105 related articles for article (PubMed ID: 22273545)
1. Design, synthesis and CoMFA studies of N1-amino acid substituted 2,4,5-triphenyl imidazoline derivatives as p53-MDM2 binding inhibitors.
Hu C; Dou X; Wu Y; Zhang L; Hu Y
Bioorg Med Chem; 2012 Feb; 20(4):1417-24. PubMed ID: 22273545
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.
Wang W; Lv D; Qiu N; Zhang L; Hu C; Hu Y
Bioorg Med Chem; 2013 Jun; 21(11):2886-94. PubMed ID: 23611770
[TBL] [Abstract][Full Text] [Related]
4. 2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation.
Bazanov DR; Pervushin NV; Savitskaya VY; Anikina LV; Proskurnina MV; Lozinskaya NA; Kopeina GS
Bioorg Med Chem Lett; 2019 Aug; 29(16):2364-2368. PubMed ID: 31196710
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.
Li J; Wu Y; Guo Z; Zhuang C; Yao J; Dong G; Yu Z; Min X; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Miao Z; Zhang W
Bioorg Med Chem Lett; 2014 Jun; 24(12):2648-50. PubMed ID: 24813735
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.
Wang W; Shangguan S; Qiu N; Hu C; Zhang L; Hu Y
Bioorg Med Chem; 2013 Jun; 21(11):2879-85. PubMed ID: 23601819
[TBL] [Abstract][Full Text] [Related]
7. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of novel orally active p53-MDM2 interaction inhibitors.
Miyazaki M; Naito H; Sugimoto Y; Yoshida K; Kawato H; Okayama T; Shimizu H; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Shiose Y; Aonuma M; Soga T
Bioorg Med Chem; 2013 Jul; 21(14):4319-31. PubMed ID: 23685175
[TBL] [Abstract][Full Text] [Related]
9. Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies.
Bandaru S; Ponnala D; Lakkaraju C; Bhukya CK; Shaheen U; Nayarisseri A
Asian Pac J Cancer Prev; 2015; 16(9):3759-65. PubMed ID: 25987034
[TBL] [Abstract][Full Text] [Related]
10. Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction.
Gureev M; Novikova D; Grigoreva T; Vorona S; Garabadzhiu A; Tribulovich V
J Comput Aided Mol Des; 2020 Jan; 34(1):55-70. PubMed ID: 31781989
[TBL] [Abstract][Full Text] [Related]
11. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
[TBL] [Abstract][Full Text] [Related]
12. Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.
Vaupel A; Bold G; De Pover A; Stachyra-Valat T; Lisztwan JH; Kallen J; Masuya K; Furet P
Bioorg Med Chem Lett; 2014 May; 24(9):2110-4. PubMed ID: 24704029
[TBL] [Abstract][Full Text] [Related]
13. Imidazoline derivatives: a patent review (2006--present).
Guan X; Hu Y
Expert Opin Ther Pat; 2012 Nov; 22(11):1353-65. PubMed ID: 23003008
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Zhang Y; Guo Z; Yao J; Dong G; Wang S; Liu Y; Chen H; Sheng C; Zhang W
Eur J Med Chem; 2011 Nov; 46(11):5654-61. PubMed ID: 21996465
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Optimization of New 3,6-Disubstitutedindole Derivatives and Their Evaluation as Anticancer Agents Targeting the MDM2/MDMx Complex.
Rezk MS; Abdel-Halim M; Keeton A; Franklin D; Bauer M; Boeckler FM; Engel M; Hartmann RW; Zhang Y; Piazza GA; Abadi AH
Chem Pharm Bull (Tokyo); 2016; 64(1):34-41. PubMed ID: 26726742
[TBL] [Abstract][Full Text] [Related]
16. Probing Alterations in MDM2 Catalytic Core Structure Effect of Garcinia Mangostana Derivatives: Insight from Molecular Dynamics Simulations.
El Habbash AI; Aljoundi A; Elamin G; Soliman MES
Cell Biochem Biophys; 2022 Dec; 80(4):633-645. PubMed ID: 36184717
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
Zheng GH; Shen JJ; Zhan YC; Yi H; Xue ST; Wang Z; Ji XY; Li ZR
Eur J Med Chem; 2014 Jun; 81():277-88. PubMed ID: 24852275
[TBL] [Abstract][Full Text] [Related]
18. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
[TBL] [Abstract][Full Text] [Related]
19. [Synthesis and antitumor activity of arylsubstituted imidazolin-2-one derivatives].
Cheng YF; Hu YZ; He QJ
Yao Xue Xue Bao; 2005 Aug; 40(8):711-6. PubMed ID: 16268505
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]